Lanean...
ACS Chemical Neuroscience Molecule Spotlight on Suvorexant
[Image: see text] Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Chemical
Society
2012
|
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3447389/ https://ncbi.nlm.nih.gov/pubmed/23024835 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cn300086a |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|